Castle Biosciences’ TissueCypher® test can offer patients with Barrett’s esophagus a clearer picture of their risk of developing esophageal cancer. Esophageal cancer is a killer. It’s the eighth most ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been selected as ...

TissueCypher is Castle’s precision medicine risk-stratification test that predicts a patient’s individual risk of progression from Barrett’s esophagus (BE) to esophageal cancer FRIENDSWOOD, ...

Garden City, NY, Feb. 20, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today announced important developments in the ...

The study, published in Gastroenterology, shows TissueCypher can increase the detection of Barrett’s esophagus (BE) patients with an initial diagnosis of low-grade dysplasia (LGD) who will progress to ...

Doctors may perform endoscopies to diagnose esophageal cancer. They may also order laboratory tests and other imaging tests, such as MRI and CT scans, to confirm the diagnosis and determine whether ...

Cancer Research U.K. has launched a large, multicenter trial to test a new device for detecting Barrett's esophagus, a condition that puts sufferers at increased risk of developing cancer of the ...

UNIONDALE, NY, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics and consumer products company, announced today ...

AURORA, Colo., Oct. 08, 2025 (GLOBE NEWSWIRE) -- EnteroTrack LLC announced that the Centers for Medicare & Medicaid Services (CMS) is paying for the company’s Esophageal String Test ® (EST), marking a ...

The MarketWatch News Department was not involved in the creation of this content. AURORA, Colo., Oct. 08, 2025 (GLOBE NEWSWIRE) -- EnteroTrack LLC announced that the Centers for Medicare & Medicaid ...